Back to search results

Aerobic Exercise and DBS for Parkinson's Disease

This study is for people with Parkinson's disease (PD) who have already received deep brain stimulation (DBS). It aims to understand how aerobic exercise, specifically cycling, affects movement, thinking, and brain activity in individuals with PD and DBS. You would participate in an eight-week cycling program, either with assistance (forced exercise) or at your own pace (voluntary exercise), after an initial eight-week control period. Researchers will measure your motor symptoms, cognitive performance, and brain activity to see how exercise helps. The study is currently unclear about its recruitment status and plans to enroll 36 participants.

Study design
This is an interventional study with 36 planned participants. It involves an eight-week control period followed by an eight-week cycling program.
What's involved
You would complete 3 in-person cycling sessions per week for eight weeks, totaling 24 sessions. You would also have measurements taken at the beginning, after the exercise period, and four weeks later.
Compensation
Not stated in the trial record.
Follow-up
Your progress will be followed for four weeks after the exercise period ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07442747

Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS

Recruiting
PHASE2Ages 18+InterventionalTreatment
The Cleveland Clinic
~36 participants
Updated 2026-07-28 on ClinicalTrials.gov
What's tested:Exercise

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (Motor Examination)
Measured over Baseline to EOT and Baseline to EOT+4 weeks
+2 more outcomes measured

Conditions

Parkinson's Disease
Deep Brain Stimulation

Explore related trials

Parkinson Disease

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Jay L Alberts, PhD · PRINCIPAL_INVESTIGATOR · The Cleveland Clinic

Who to contact

MacKenzie Dunlap
[email protected]
216-219-3949
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinical diagnosis of Parkinson's disease
Previous placement of bilateral Medtronic Percept DBS as standard of care treatment for PD
Clinically optimized DBS parameters for one month prior to enrollment
Ability to ambulate with or without an assistive device for 5 continuous minutes
Willingness to withhold antiparkinsonian medication and DBS stimulation for outcomes assessments

Exclusion

Neurocognitive impairment that compromises the ability to provide informed consent
Neurological disease other than Parkinson's disease (i.e. multiple sclerosis, stroke)
Recommendation for medical clearance using the American College of Sports Medicine (ACSM) Preparticipation Health Screen:
A musculoskeletal issue (arthritis, osteoporosis, back problem) that would limit one's ability to engage in exercise
Current cardiac arrhythmia

What this trial measures

  • Movement Disorder Society-Unified Parkinson's Disease Rating Scale (Motor Examination)Baseline to EOT and Baseline to EOT+4 weeks

    Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III: Motor Examination score, measured off medication. Range of scores is 0 to 132, with lower score indicating better motor function. Change in MDS-UPDRS III score from baseline to end-of-treatment (EOT) and baseline to EOT+4 weeks.

  • Relative Root Mean Square Error of a Grip Force Tracking TaskBaseline to EOT and Baseline to EOT+4 weeks

    Participants are required to modulate the precision grip force of their dominant hand to match a target trajectory on a computer screen. Relative root mean squared error quantifies deviation from the target force trajectory. Values are normalized for maximum target amplitude, with lower values indicating decreased error.

  • Local Field Potential Subthalamic Nucleus Beta at RestBaseline to EOT and Baseline to EOT+4 weeks

    Normalized beta band activity is reported as the change in resting-state STN beta band (13-30Hz) power. Higher beta band suggests increased pathological electrical synchrony.